HomeAIM • NYSEAMERICAN
add
AIM ImmunoTech Inc
Previous close
$1.52
Day range
$1.48 - $1.58
Year range
$1.26 - $20.35
Market cap
4.34M USD
Avg Volume
77.41K
P/E ratio
-
Dividend yield
-
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 26.00K | -25.71% |
Operating expense | 2.40M | -46.74% |
Net income | -3.28M | 11.24% |
Net profit margin | -12.63K | -19.48% |
Earnings per share | -1.57 | 77.21% |
EBITDA | -2.39M | 45.93% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 2.41M | -66.55% |
Total assets | 5.49M | -59.57% |
Total liabilities | 11.57M | 8.38% |
Total equity | -6.08M | — |
Shares outstanding | 2.85M | — |
Price to book | -0.69 | — |
Return on assets | -127.14% | — |
Return on capital | 163.57% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -3.28M | 11.24% |
Cash from operations | -5.08M | -63.31% |
Cash from investing | 296.00K | -11.38% |
Cash from financing | 6.65M | 4,756.93% |
Net change in cash | 1.87M | 170.90% |
Free cash flow | -7.41M | -315.84% |
About
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
Founded
1966
Headquarters
Website
Employees
22
